Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Finance

Ramping up Rubius

Why Rubius chose to beef up its platform rather than hurrying into the clinic

June 23, 2017 10:16 PM UTC

Rubius Therapeutics Inc. decided to delay its entry to the clinic to bring a broader set of compounds forward simultaneously. Now armed with an $120 million series B round, the biotech has the resources to do so.

The untranched round from Flagship Pioneering and undisclosed institutional investors was announced June 21...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Rubius Therapeutics Inc.